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Abstract 
Background: The purpose is to investigate the clinical significance of body morphomics changes in stage III–IV oro-
pharyngeal cancer patients during concurrent chemoradiotherapy (CRT).
Methods: Fifty patients who underwent CRT were selected for body composition analyses by either availability of 
pre/post treatment DEXA scans or a novel CT-based approach of body morphomics analysis (BMA). BMA changes 
(lean psoas and total psoas area) were compared to total lean body mass changes by DEXA scans using two-sample  
t tests. Pearson correlation was used to compare the BMA measures to head and neck specific quality of life outcomes. 
Cox hazards model was used to predict mortality and tumor recurrence.
Results: Clinically significant declines in total psoas area and lean body mass of similar magnitude were observed in 
both BMA and DEXA cohorts after CRT. Loss of psoas area (P < 0.05) was associated with greater frailty and mobility 
issues (3 out of 15 UWQOL domains). Total psoas area is more sensitive for local recurrence than weight changes and 
T-stage on multivariate analyses.
Conclusions: BMA specifically evaluating psoas area appears to correlate with head and neck cancer quality of life 
physical domains. Pre- and post-treatment total psoas area at L4 appears prognostic for tumor recurrence.
© 2016 Wang et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made.
Background
Total body composition (TBC) is an analysis of patient 
muscle and fat distribution, and represents a global 
assessment of their state of health. Adverse TBC changes 
are widespread among cancer patients including those 
with breast cancer, lung cancer, gastrointestinal malig-
nancies and gynecologic cancer (Awad et  al. 2012; Fou-
ladiun et  al. 2005; Gil et  al. 2006; Harvie et  al. 2003; 
Jacquelin-Ravel and Pichard 2012; Silver et  al. 2007; 
Tan et  al. 2009; Smith 2004; Demark-wahnefried et  al. 
2001). Fluctuations in TBC during cancer treatment are 
patient-specific and generally vary according to disease 
site and treatment modality. Furthermore, TBC changes 
have been shown to be associated with impairments 
in physical function (Brown et  al. 2005), quality of life, 
resistance to therapy and worse prognosis in some cancer 
patient populations (Fearon et al. 2011; Wallengren et al. 
2013; Fearon et  al. 2006; Couch et  al. 2007; Tsai 2012). 
Given the potential clinical consequences of during and 
post-treatment TBC alterations, further understanding 
these changes and evaluating the potential need for inter-
vention in response to TBC alterations is important.
Head and neck cancer patients, in particular, experi-
ence significant treatment and cancer-related weight loss 
due to a multifactorial metabolic syndrome (Silver et al. 
2007). More than 70  % of this weight loss is attributed 
to loss of muscle mass (Silver et al. 2007), which occurs 
Open Access
*Correspondence:  shrutij@med.umich.edu 
1 Department of Radiation Oncology, University of Michigan, UHB2C447, 
SPC 5010, 1500 East Medical Center Drive, Ann Arbor, MI 48109-5010, USA
Full list of author information is available at the end of the article
Page 2 of 9Wang et al. SpringerPlus  (2016) 5:429 
despite adequate nutritional supplementation. This loss 
of lean muscle mass without a corresponding loss in fat 
mass, known as sarcopenia, correlates with worse over-
all prognosis in oropharyngeal cancer patients (Adelstein 
et  al. 2000). Better understanding of TBC in head and 
neck cancer patients is necessary to design interventions 
that may improve their quality of life, functional status, 
and overall prognosis. Moreover, there is need for a con-
venient and accurate technique to evaluate changes in 
body composition. Dual-energy X-ray absorptiometry 
(DEXA) has been the gold standard for determining total 
body composition; however, its accuracy may be limited 
in patients undergoing large changes in volume status, 
such as with head and neck cancer patients undergoing 
treatment (Jackson et al. 2013). Past studies characteriz-
ing changes in TBC have utilized different methods based 
on fundamentally different techniques, including plain 
anthropometric measurements (Hyltander et  al. 1991; 
Richards et al. 2012), neutron activation analysis (MacFie 
and Burkinshaw 1987), bioelectric impedance measure-
ments (Simons et  al. 1995), computerized tomography 
(Smith 2004), and DEXA (Jackson et  al. 2013; Maturo 
et al. 2003; Koch 1998). These methods may be difficult to 
obtain at the respective institution, and they have yielded 
inconsistent results due to intrinsic measurement limita-
tions and variations (Fouladiun et al. 2005).
A recently developed novel technique utilizes a high 
throughput analysis of body composition characteristics 
(body morphomics analysis) to assess patient frailty. This 
innovative CT-based approach offers convenience for the 
patients and limits additional tests as most patients with 
cancer undergo routine imaging with CT before and after 
chemoradiation. Furthermore, body morphomics offers 
significant cost saving implications by reducing addi-
tional tests and supports patient-centered individualized 
cancer care planning.
Body morphomics analysis can rapidly and accurately 
characterize the changes in regional body composition 
in cancer patients, and has shown a strong correlation 
between trunk muscle (psoas) size and mortality in mul-
tiple clinical settings, including postoperatively following 
liver transplant surgery, abdominal aneurysm surgery, 
and inpatient general surgery (Zarinsefat et al. 2014; Levi 
et al. 2014; Waits et al. 2014; Englesbe et al. 2013; Sheetz 
et al. 2013). Core muscle size has similarly shown prog-
nostic value in patients with esophageal cancer (Sheetz 
et al. 2013), adrenocortical carcinoma (Miller et al. 2012), 
and melanoma (Sabel et al. 2011). The role of body mor-
phomics in head and neck cancer patients treated with 
chemoradiotherapy (CRT), who experience significant 
metabolic disturbances during treatment, remains unex-
plored to date. Furthermore, to our knowledge no study 
has looked at the correlation between regional changes 
in psoas area as determined by CT with changes in total 
body composition as determined by DEXA scan, the cur-
rent gold standard for body composition analysis. This 
is important to help us understand whether analysis of a 
single slice CT is sufficient for predicting changes in total 
body composition.
In this study of locally advanced head and neck can-
cer patients undergoing concurrent chemoradiation, we 
aim to characterize the changes in body morphomics 
(total psoas area, lean psoas area, psoas muscle density, 
HU) before and after CRT by determining the associa-
tion between these changes with patient-reported quality 
of life (QoL) and tumor related outcomes. We hypoth-
esize that decline in psoas area as determined by CT at 
L4 vertebral body level is associated with worse quality 
of life and tumor related outcomes. Our second aim was 
to determine whether changes in psoas area correlate 
with changes in total body composition as determined by 
DEXA scan. We hypothesize that psoas area will decline 
similarly to TBC changes of lean body mass by DEXA 
scan during CRT.
Methods
After obtaining University of Michigan Institutional 
Review Board approval, 93 patients were enrolled in 2 
consecutive prospective trials of organ sparing chem-
otherapy with intensity-modulated radiation therapy 
(IMRT) for locally advanced oropharyngeal cancer 
from 2003 to 2011. Eligibility included stages III to IV 
squamous cell carcinoma of the oropharynx, no prior 
therapy, Karnofsky performance status ≥60, and pri-
mary therapy with CRT. Details of therapy have been 
previously published (Hunter et  al. 2013; Feng et  al. 
2010). Briefly, all patients required treatment of bilat-
eral neck. All patients received concurrent weekly 
chemotherapy with carboplatin (area under curve = 1) 
and paclitaxel (30 mg/m2). None received induction or 
adjuvant chemotherapy. The IMRT prescription doses 
were 70 Gy to the primary tumor and involved lymph 
nodes, 59–63  Gy to high-risk nodal regions and the 
anatomic compartments around the gross tumor vol-
umes, and 56  Gy to low-risk nodal regions, all deliv-
ered in 35 fractions. Priority was given during planning 
to spare the noninvolved parts of the major salivary 
glands, the oral cavity, pharyngeal constrictor muscles, 
larynx, and the esophagus, to minimize late xerostomia 
and dysphagia. Feeding tubes were inserted if weight 
loss during therapy approached 10  %. All procedures 
were in accordance with the ethical standards of the 
committee on human experimentation of the institu-
tion or in accord with the Helsinki Declaration of 1975 
as revised in 1983. Details of the radiation treatment 
planning, the dosimetric and functional results in these 
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patients have previously been published (Hunter et  al. 
2013; Feng et al. 2010).
In a separate study, after obtaining University of Michi-
gan Institutional Review Board Approval, 12 patients 
with locally advanced squamous cell head and neck can-
cer were enrolled in a prospective study assessing the 
overall changes in total body composition using DEXA. 
This cohort is a subset of a larger cohort that is being 
accrued for a study assessing the impact of exercise train-
ing on changes in total body composition for patients 
receiving concurrent chemoradiation therapy (CCRT) for 
locally advanced head and neck cancer. Eligibility crite-
ria included patients with American Joint Committee on 
Cancer stage II–IV squamous cell head and neck cancer 
receiving CCRT as first-line treatment without surgery. 
All patients underwent a preliminary nutritional assess-
ment by a dietician before initiation of treatment. Six 
patients received a percutaneous endoscopoic gastros-
tomy (PEG) tube before initiation of radiation therapy, 
and an additional 3 patients received a PEG tube during 
radiation therapy for enteral nutrition. If a patient expe-
rienced >5 to 10  % decrease in body mass during the 
course of treatment, a nutritionist was consulted. All pro-
cedures were in accordance with the ethical standards of 
the committee on human experimentation of the institu-
tion or in accord with the Helsinki Declaration of 1975 as 
revised in 1983. Details of the study have been previously 
published (Jackson et al. 2013).
Forty-three of ninety-three patients with PET/CT 
scans obtained pre-treatment and within 3–6 months fol-
lowing completion of treatment, for whom the CT scan 
included the psoas muscle, were eligible for the present 
study, and other fifty patients were initially treated at 
outside institutions and their staging CT scans were not 
available for analysis. Twelve patients with DEXA-scan 
based body composition analyses obtained pre-CRT and 
2  months post-CRT follow-up were also enrolled (Jack-
son et al. 2013). Clinical data including age, sex, height, 
weight, dosimetric data, smoking status, tumor recur-
rences, mortality, and cancer stage were obtained for the 
patients.
Body morphomics analysis (BMA) was performed on 
pre- and post-treatment chest and abdominal computed 
tomography (CT) in a semi-automated fashion using 
algorithms programmed in MATLAB v13.0. To deter-
mine the cross sectional areas and densities of the left 
and right psoas muscle at the level of the fourth lumbar 
vertebra (L4), individual vertebral levels were initially 
identified on each patient’s PET-CT scan in sagittal sec-
tion. Individual transverse imaging slice at the superior 
aspect of L4 were selected and the borders of the left and 
right psoas muscle were outlined using an edge-detect-
ing algorithm, and verified by trained investigators. The 
areas of the resulting enclosed regions were then com-
puted and summed to yield the total cross-sectional 
area of the psoas muscle (Englesbe et al. 2013). Average 
density in Houndsfield Units (HUs) of the psoas muscle 
in the selected regions was also measured. To adjust for 
fatty infiltration of the psoas muscle, the average density 
was used to calculate the total cross-sectional area of the 
psoas muscles, excluding fatty infiltration (lean psoas 
muscle) (Englesbe et al. 2012).
Head-and-neck cancer and treatment-related QoL was 
assessed by 2 validated instruments: the Head and Neck 
QOL (HNQOL) (Koch 1998) and University of Wash-
ington QOL (UWQOL) (Hassan and Weymuller 1993), 
version 3. Briefly, UWQOL (version 3) is a validated, 
self-administered, and multi-factorial, questionnaire that 
provides questions specific to head and neck cancer. Ten 
questions domains of UWQOL included: pain, appear-
ance, activity, recreation, employment, chewing, speech, 
taste, saliva, and mucous. Scoring is scaled so that a score 
of 50 represents the worst possible response, and a score 
of 10 represents the best possible response. Scoring is 
scaled in equal increments from ten to fifty to reflect the 
number of possible responses. Thus the pain domain has 
5 possible responses, which are scored as 10, 20, 30, 40, 
and 50.
The Head and Neck QOL is a validated and self-
administered questionnaire also specific to head and 
neck cancer. This questionnaire had four domains: eating 
(6 items), communication (4 items), pain (4 items), and 
emotion (6 items). Scoring is scaled so that a score of 4 
represents the worst possible response, and a score of 0 
represents the best possible response. Scoring is scaled 
in equal increments from 0 to 4 to reflect the five pos-
sible responses. For example, within the communication 
domain, “ability to talk to other people” has 5 possible 
responses, which are scored as 0, 1, 2, 3, and 4. HNQOL 
and UWQOL questionnaires were administered at 6 time 
intervals: before initiation of treatment and at 3, 6, 12, 18, 
and 24 months after treatment.
DEXA measurements of total lean body mass and body 
morphomics parameters of total psoas area and lean 
psoas area were the main variables of interest from the 
respective analysis. Normal distribution of the fore men-
tioned variables was verified with Q–Q plots. BMI cat-
egories of normal (18.5–24.9), overweight (25–29.9), and 
obese (≥30.0) were used to stratify for further analysis 
of weight loss. Changes in weight, BMI, total psoas area, 
lean psoas area, and lean body mass were characterized 
with mean, standard deviation, percent change, two-
sample t test, and 95 % confidence interval. Two-sample t 
test was employed to compare the percent change of lean 
body mass with that of total and lean psoas area. Cox 
proportional hazards model as used to assess the effect 
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of total psoas area on tumor recurrence and mortality. 
The Pearson’s correlation coefficient was calculated to 
evaluate associations between changes in BMA measures 
from pre-treatment to 3  months post-treatment with 
changes in UWQOL and HNQOL from pre-treatment to 
6 months post-treatment. We chose to analyze the qual-
ity of life associations at the fore mentioned time frame 
because patients were still recovering from CRT side 
effects at 3 and at 12–24 months, deterioration in quality 
of life began to return to pre-treatment levels. A signifi-
cance level of α =  0.05 was used. All statistical analysis 
was performed using SPSS (IBM Corp. Released 2013. 
IBM SPSS Statistics for Windows, Version 22.0. Armonk, 
NY: IBM Corp.).
Consent
Written informed consent was obtained from the 
patients to participate in this study and for publication of 
this research article and any accompanying images.
Results
Forty-three of the 93 patients enrolled in prospective 
phase II chemo-IMRT had pre-treatment and post-
treatment follow-up PET/CT scans available for mor-
phomics analysis and thirty-eight of the forty-three had 
also prospectively completed the UWQOL and HNQOL 
questionnaires. Twelve other patients had pre- and post-
treatment DEXA scans available for total body com-
position analysis. Characteristics of the two groups are 
summarized in Table  1. DEXA study patient group and 
BMA group are similar with respect to age, sex, tumor 
site, AJCC stage, and IMRT dose. Clinical and demo-
graphic similarities between the two groups allow for 
comparison between total body composition changes 
and total psoas muscle area changes.
Clinically significant lean muscle mass decline was 
seen in both BMA and DEXA cohorts, shown in Table 2. 
Decrease in overall lean body mass by DEXA scan was 
10.2  %, which is comparable to the degree of decline in 
total psoas area by body morphomics of 10.9  %. Lean 
psoas area on the other hand seemed to over-estimate 
the degree of lean body mass loss; it decreased by 14.1 % 
after CRT. Psoas Houndsfield unit (HU), a measure of 
muscle density, decreased by 9.2 %, which is indicative of 
increase in fatty infiltration and decline in muscle quality 
after CRT. Decreases in weight were similar between the 
DEXA and BMA group (11.7 and 10.33 %, respectively). 
Summary of body morphomics changes are shown in 
Table 3.
In our BMA cohort, there were nine patients with 
tumor recurrences and six deaths. In univariate analy-
sis, greater percent decline in total psoas area was cor-
related with higher risk of tumor recurrence [hazard 
ratio (HR) = 1.117; 95 % CI 1.018, 1.225; P = 0.019] and 
mortality (HR = 1.127; 95 % CI 1.018, 1.225; P = 0.019), 
Table  4. The interpretation is for each 1  % loss of total 
psoas area, the risk of tumor recurrence and mortal-
ity increases by 11.7 and 12.7 % respectively. Given that 
our patients on average loose 10.9 % of total psoas area, 
the risk of tumor recurrence and mortality is 127.3 and 
138.2 %, respectively, higher relative to a patient without 
any changes in total psoas area.
Higher percent decrease in weight in univariate 
analyses was correlated with higher risk of mortality 
(HR =  1.111; 95  % CI 1.001, 1.233; P =  0.047) but not 
tumor recurrence (P = 0.163). As expected, T-stage also 
correlated with tumor recurrence (HR = 2.048; 95 % CI 
1.024–4.095; P = 0.043) and mortality (HR = 3.891; 95 % 
CI 1.161–13.046; P =  0.028) in univariate analyses. The 
interpretation is for each increase in stage (i.e. from stage 
III to IV), the risk of tumor recurrence and mortality 
increases by 104.8 and 289.1  % respectively. Lean psoas 
area and psoas density (HU) did not correlate with tumor 
recurrence or mortality in univariate analysis.
In multivariate analysis adjusted for patient age, per-
cent decrease in weight and tumor stage, greater decline 
in total psoas area was a significant predictor of tumor 
Table 1 Clinical characteristics and  total body composi-
tion changes
LBM lean body mass, FBM fat body mass, CCRT concurrent chemo-radiation 
therapy, Gy gray dosage
DEXA study Body morphomics 
analysis
Sample size N = 12 N = 43
Age (years) 57 (±8.1) 57 (±7)
Weight (kg) 93 (±12.6) 92 (±17.4)
BMI 27.1 (±3.0) 29.1 (±5)
LBM (kg) 59.2 (±7.8) –
FBM (kg) 30.6 (±7.5) –
Total psoas area (mm2) – 2811 (±726)
Lean psoas area (mm2) – 1407 (±356)
Male 12 (100.0) 36 (95.0)
Female 0 (0.0) 2 (5.0)
Tumor site
Base of tongue 6 (50.0) 20 (53.0)
Tonsil 4 (33.3) 18 (47.0)
Other 2 (16.7) –
AJCC stage
III 7 % 5 %
IVA 83 % 95 %
IVB – –
Treatment modality, CCRT 12 (100.0) 38 (100.0)
IMRT dose, Gy 70.0 (±0.0) 70.0 (±0.0)
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recurrence (HR = 1.148; 95 % CI 1.005, 1.311; P = 0.042), 
but not mortality (P = 0.173), Table 5. While tumor stage 
was a significant predictor in multivariate analysis of 
tumor recurrence, when adjusting for total psoas area as 
well as patient age, and weight, T-stage was not signifi-
cant in predicting mortality among patients (HR = 3.054; 
95 % CI 0.960, 9.717; P = 0.094). On multivariate analy-
ses adjusted for age, percent decrease in total psoas area, 
and T-stage, percent decline in weight was not a signifi-
cant predictor of either tumor recurrence (P = 0.502) or 
mortality (P = 0.787). Of note, gender was not used as a 
covariate in multivariate analyses due to small number of 
females in the cohort (n = 2).
AIC scores were calculated to determine the relative 
contribution of each covariate to model strength. AIC 
scores in Table 5 reflect model strength when the given 
covariate is removed from the model; higher AIC indi-
cates greater importance of the removed covariate. Fac-
tors with P value <0.05 in the multivariate model are 
significant predictors of tumor recurrence or mortal-
ity. To shed light on the relative contribution of a fac-
tor, the AIC was calculated by the removal of that factor 
from the final model. Higher values of AIC indicates 
greater importance of the omitted factor. Total psoas 
area is a strong predictor, slightly more contributory 
than T-stage, of tumor recurrence (AIC-Psoas = 44.104; 
AIC-stage = 43.682).
Decrease in psoas muscle area from pre-treatment to 
first follow-up was significantly correlated with dete-
rioration in 3 out of 15 UWQOL domains (activity, rec-
reation/entertainment, and swallowing, all P  <  0.05) as 
well as a single item in HNQOL regarding concerns for 
cancer related physical problems (P < 0.05) from pre- to 
6  months post-treatment, Table  6. As expected, decline 
in psoas area are correlated with quality of life domains 
relating to mobility and maintenance of muscle function 
(i.e. swallowing). Body weight and BMI are correlated 
Table 2 DEXA total body composition changes
In the DEXA scan cohort, changes in BMI, weight and lean body mass were 
assessed at pre- and 2 months post-treatment follow-up
Net change Percent change P value
BMI 1.75 (±2.2) 5.96 <0.05
Weight (kg) 11.2 (±6.9) 11.70 <0.05
Lean body mass (kg) 6.1 (±6.8) 10.20 0.001
Table 3 Body morphomics changes
Changes in body morphomics measures were assessed from pre-treatment to 3 months post-up





Percent change (95 % CI) P value
Weight (kg) 92 ±17 82 ± 15 −10.33 (−8.05, −12.61) <0.001
Body mass index (BMI)* 29.1 ± 5 26.7 ± 4.2 −9.71 (−7.41, −12.01) <0.001
 Normal (N = 8) 23.2 ± 1.14 21.2 ± 2.89 −8.62 (−5.6, −11.64) <0.05
 Overweight (N = 16) 28.20 ± 1.41 25.72 ± 2.03 −8.79 (−7.39, −10.19) <0.001
 Obese (N = 19) 34.71 ± 3.18 29.86 ± 3.03 −13.97 (−11.7, −16.24) <0.001
Bone Marrow Density (L4) 159 ± 42.1 159 ± 41.3 0 –
Total psoas area (mm2) 2811 ± 726 2492 ± 626 −10.88 (−8.70, −13.06) <0.001
Left psoas area (mm2) 1407 ± 356 1244 ± 311 −10.75 (−7.73, −13.77) <0.001
Right psoas area (mm2) 1404 ± 385 1248 ± 328 −10.74 (−8.45, −13.03) <0.001
Psoas density (HU) 52.0 ± 7.1 47.2 ± 7.9 −9.16 (−4.42, −13.9) <0.005
Lean psoas (HU × mm2) 1130 ± 300 973 ± 270 −14.09 (−11.07, −17.01) <0.001
Table 4 Univariate analysis of  risk factors and  adverse 
patient outcomes
Measure P value HR (95 % CI)
(A) Tumor recurrence
 Total psoas area (% decline) 0.019 1.117 (1.018–1.225)
 Weight (% decline) 0.163 1.064 (0.975–1.160)
 Age 0.43 0.961 (0.871–1.061)
 T-stage 0.043 2.048 (1.024–4.095)
 Lean psoas area (% decline) 0.14 1.047 (0.985–1.114)
 Psoas HU (% decline) 0.933 0.988 (0.957–1.041)
(B) Mortality
 Total psoas area (% decline) 0.043 1.127 (1.004–1.266)
 Weight (% decline) 0.047 1.111 (1.001–1.233)
 Age 0.0514 1.037 (0.929–1.157)
 T-stage 0.028 3.891 (1.161–13.046)
 Lean psoas area (% decline) 0.147 1.060 (0.980–1.148)
 Psoas HU (% decline) 0.656 1.010 (0.966–1.057)
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with 4 out of 14 UWQOL domains (general pain, rec-
reation/entertainment, speech, and taste, all P  <  0.05) 
and 3 out of 14 UWQOL domains (general pain, recrea-
tion/entertainment, and speech, all P < 0.05) respectively 
from pre- to 6  months post-treatment. No significant 
correlations were found between body weight and BMI 
with HNQOL. Summary of the correlations of changes 
in body morphomics with quality of life are shown in 
Table 6.
It is notable that tumor stage did not yield significant 
correlations with either HNQOL or UWQOL from pre- 
to 6  months post-treatment. Furthermore, common 
toxicity criteria (Trotti et al. 2000) also did not yield sig-
nificant correlations with HNQOL or UWQOL from pre 
to 6 months post-treatment.
Discussion
This is the first study to analyze the changes in body com-
position through a novel analytic morphomics technique 
utilizing single slice PET/CT at L4 in oropharyngeal 
cancer patients undergoing chemoradiation. We inves-
tigated the potential for using total psoas area by body 
morphomics to measure TBC changes. The study found 
similar declines in total lean body mass by DEXA, the 
current gold standard for TBC measurements (Jackson 
et  al. 2013), and total psoas area by body morphomics, 
indicating that perhaps single slice CT total psoas area at 
L4 may adequately capture TBC lean body mass changes. 
Furthermore, body morphomics is performed on routine 
staging CT scans, offering patients convenience and lim-
its the need for additional testing.
Table 5 Mulitivariate analysis of risk factors and adverse patient outcomes
Factor (% decrease) Tumor Recurrence Mortality
Hazard ratio (95 % CI) P AIC Hazard ratio (95 % CI) P AIC
Total psoas area 1.148 (1.005–1.311) 0.042 44.104 1.111 (0.955–1.292) 0.173 40.657
Weight 0.966 (0.875–1.068) 0.502 41.496 1.016 (0.908–1.136) 0.787 40.341
Age 0.909 (0.805–1.026) 0.909 41.723 1.037 (0.891–1.207) 0.643 40.308
T-stage 2.305 (1.059–5.018) 0.035 43.682 2.878 (0.836–9.914) 0.094 41.387
Table 6 Summary of body morphomics and quality of life correlations
Correlations between changes in body morphomics measures from pre-treatment to 3 months post-treatment with UWQOL and HNQOL measures from pre- to 
6 months post-treatment. Of note, “concerns regarding cancer related physical problems” was the only measure that correlated with BMA out of the 4 HNQOL domains
Statistically significant associations between weight, BMI, and body morphomic parameter with quality of life domains are underlined
Body weight Body mass index Psoas muscle
Pearson’s r P value Pearson’s r P value Pearson’s r P value
UW QOL
Activity −0.219 0.213 −0.189 0.284 −0.399 0.019
Chewing −0.324 0.062 −0.289 0.097 −0.284 0.104
Disfigurement −0.033 0.853 0.077 0.665 0.197 0.264
Employment −0.056 0.753 −0.0004 0.998 0.033 0.853
General pain −0.404 0.018 −0.374 0.029 −0.226 0.198
Mouth pain −0.21 0.233 −0.197 0.264 −0.137 0.44
Mucus amount −0.132 0.456 −0.119 0.503 −0.239 0.173
Mucus consistency 0.091 0.609 −0.08 0.653 0.014 0.937
Recreation/entertainment −0.423 0.013 −0.378 0.028 −0.438 0.0096
Saliva amount −0.031 0.862 0.0001 0.999 −0.048 0.787
Saliva consistency 0.159 0.369 0.217 0.218 0.157 0.375
Speech −0.398 0.0197 −0.37 0.031 −0.252 0.151
Swallowing −0.240 0.172 −0.226 0.199 −0.401 0.019
Taste −0.338 0.05 −0.306 0.078 −0.066 0.711
Throat Pain −0.194 0.272 −0.2 0.256 −0.152 0.291
UM HNQOL
Emotion domain: concerns regarding…
 Cancer related physical problems −0.143 0.419 −0.129 0.467 −0.453 0.007
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This study found significant declines in total psoas 
area, lean psoas area, and psoas HU from pre-treatment 
to 3  months post-treatment follow-up. Psoas muscle 
area decline is clinically significant because it correlates 
with deterioration in patient reported physical activity 
(3 out of 15 UWQOL domains) and concerns regarding 
cancer related physical problems (1 out of 4 HNQOL 
domains) from pre- to 6 months post-treatment on uni-
variate analysis. Furthermore, decline in total psoas area 
independently predicts tumor recurrence in univariate 
and multivariate analysis adjusted for age, tumor stage, 
and decline in weight. In multivariate analysis, psoas 
muscle area loss also appears to be a greater contribu-
tor to tumor recurrence than T-stage, similar to results 
reported by Sheetz et  al. (2013) who found lean psoas 
area to be a greater contributor than stage.
We found that lean psoas area and psoas density (HU) 
did not correlate with tumor recurrence or mortality in 
univariate analysis. This finding is in contrast to results 
reported by Sheetz et al. who conducted a similar study 
with esophageal cancer patients undergoing esophagec-
tomy. They found lean psoas area to be predictive of 
overall survival and disease free survival on univariate 
analysis and multivariate analysis (Sheetz et  al. 2013). 
This discrepancy shows that the sensitivities of differ-
ent body morphomics measures (total psoas area vs. 
lean psoas area) in different clinical settings are not fully 
understood and require further research.
This study also found significant changes in body 
weight from pre-CRT baseline to post-CRT, a degree of 
loss that is comparable to findings from similar studies 
(Jackson et al. 2013). From our study, the effects of weight 
loss appear to hold less clinical significance than decline 
in total psoas area. Decline in body weight did not pre-
dict tumor recurrence in univariate or multivariate analy-
sis. On univariate analysis, weight loss is associated with 
greater risk of mortality; however, this relationship is not 
significant on multivariate analysis adjusted for age, per-
cent decline in total psoas area, and T-stage. In the mul-
tivariate models, psoas area also appears to be a stronger 
predictor for tumor recurrence than weight loss. Weight 
loss correlated with deterioration in general quality of life 
(i.e. general pain, recreation and entertainment, taste, 
and speech) domains from pre- to 6 months post-treat-
ment on univariate analysis. This is in contrast with qual-
ity of life deterioration associated with total psoas area, 
which are specific to frailty and mobility.
There is a need for measurements of BMI to better 
quantify the interpersonal variations in the significance 
of weight loss (Fearon et  al. 2006) and few studies have 
examined the changes in BMI in cancer patients in gen-
eral. We examined the changes in BMI in oropharyngeal 
cancer patients and found that on average BMI decreased 
by 9.7  %. By stratifying patients into BMI categories of 
obese, overweight, and normal, we found distinct pat-
terns of weight losses specific to each group. Decrease 
in BMI correlated with declines in 3 out of 15 UWQOL 
domains from pre- to 6  months post-treatment on uni-
variate analysis. There is significant overlap in the asso-
ciated QOL domains between BMI and weight loss. This 
indicates that future studies may only need to focus on 
one or the other when characterizing quality of life 
outcomes.
Our finding that total psoas area predicted mortality 
in oropharyngeal cancer patients on univariate analysis 
is not surprising given total psoas area decline is associ-
ated with increased mortality in multiple clinical settings 
(Zarinsefat et al. 2014; Levi et al. 2014; Waits et al. 2014; 
Englesbe et al. 2013; Sheetz et al. 2013; Miller et al. 2012; 
Sabel et  al. 2011). It is surprising that decline in psoas 
area independently predicted tumor recurrence adjusted 
for age, T-stage, and weight loss. This is the first study to 
our knowledge to delineate this relationship. It is possi-
ble that patients who are more likely to experience tumor 
recurrence may have declines in body composition that 
portends the recurrence and can be readily detected by 
body morphomics; thus, in that subset of patients, body 
composition changes is reflectively of ongoing metabolic 
and inflammatory derangements of the patients.
Despite these findings, there are several limitations in 
this study. The study cohort represents a subset of pre-
viously published patients (Feng et al. 2010); our cohort 
size was limited by inclusion criteria of having pre- and 
post-treatment PET/CT as well as prospective comple-
tion of UWQOL and HNQOL questionnaires. Further-
more, our sample size (n =  38) limits the possibility of 
multivariate analysis for quality of life correlations. 
Future studies with larger patient cohorts are required 
to better delineate the relationship between decline in 
total psoas and deterioration in quality of life. Such stud-
ies may allow clinicians to prospectively identify patients 
who should undergo exercise and nutritional interven-
tions to improve quality of life into survivorship (Jackson 
et al. 2013).
In conclusion, to better aid in the understanding of 
changes in detailed body composition, body morpho-
mics analysis is an accurate and convenient method for 
patients to characterize body composition changes in 
cancer patients using the patient’s staging CT (or PET/
CT) scans. Notably, body morphomics appears to be a 
more sensitive measure of adverse outcomes (i.e. tumor 
recurrences) than tumor stage and weight loss. Body 
morphomics is also associated with clinically significant 
changes in QOL up to 6 months post-CRT.
Given the accessibility of data in already existing stag-
ing and follow-up CT scans of head and neck cancer 
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patients and ability to accurately provide body com-
position data using body morphomics analysis, this 
methodology may prove to be a vital instrument in the 
longitudinal evaluation of cancer patients. It could help 
clinicians identify patients who are at increased risk 
for cachexia as well as monitor the effects of behavioral 
interventions (diet and exercise) in cancer patients. More 
research in body morphomics in cancer patients is neces-
sary to better understand its broad clinical application.
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